KR102043077B1 - 알파 ７ 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성을 예측하는 바이오마커 - Google Patents
알파 ７ 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성을 예측하는 바이오마커 Download PDFInfo
- Publication number
- KR102043077B1 KR102043077B1 KR1020147010115A KR20147010115A KR102043077B1 KR 102043077 B1 KR102043077 B1 KR 102043077B1 KR 1020147010115 A KR1020147010115 A KR 1020147010115A KR 20147010115 A KR20147010115 A KR 20147010115A KR 102043077 B1 KR102043077 B1 KR 102043077B1
- Authority
- KR
- South Korea
- Prior art keywords
- snp
- seq
- delete delete
- individual
- nachr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CN(*C1C*)IC1I Chemical compound CN(*C1C*)IC1I 0.000 description 4
- RHOOLJLEYYXKTK-UHFFFAOYSA-N Cc1cnc(C)nc1 Chemical compound Cc1cnc(C)nc1 RHOOLJLEYYXKTK-UHFFFAOYSA-N 0.000 description 1
- BGVTUIRPHLSMJU-UHFFFAOYSA-N Cc1nnc(C)cc1 Chemical compound Cc1nnc(C)cc1 BGVTUIRPHLSMJU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161549319P | 2011-10-20 | 2011-10-20 | |
| US61/549,319 | 2011-10-20 | ||
| PCT/IB2012/055692 WO2013057687A2 (en) | 2011-10-20 | 2012-10-18 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20140081822A KR20140081822A (ko) | 2014-07-01 |
| KR102043077B1 true KR102043077B1 (ko) | 2019-11-11 |
Family
ID=47297333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020147010115A Active KR102043077B1 (ko) | 2011-10-20 | 2012-10-18 | 알파 ７ 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성을 예측하는 바이오마커 |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP2768507B1 (enExample) |
| JP (1) | JP6162705B2 (enExample) |
| KR (1) | KR102043077B1 (enExample) |
| CN (1) | CN103930112B (enExample) |
| AU (1) | AU2012324458B2 (enExample) |
| BR (1) | BR112014007485B1 (enExample) |
| CA (2) | CA3083244C (enExample) |
| EA (1) | EA034964B1 (enExample) |
| ES (1) | ES2776996T3 (enExample) |
| IN (1) | IN2014CN03647A (enExample) |
| JO (1) | JO3766B1 (enExample) |
| MX (1) | MX374644B (enExample) |
| TW (1) | TWI635861B (enExample) |
| WO (1) | WO2013057687A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| RS63430B1 (sr) | 2010-10-01 | 2022-08-31 | Modernatx Inc | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene |
| EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DK3682905T3 (da) | 2011-10-03 | 2022-02-28 | Modernatx Inc | Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf |
| DE12858350T1 (de) | 2011-12-16 | 2021-10-07 | Modernatx, Inc. | Modifizierte mrna zusammensetzungen |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| EP4413974A3 (en) | 2014-10-20 | 2024-10-09 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
| PT3439661T (pt) | 2016-04-07 | 2021-09-30 | Oyster Point Pharma Inc | Métodos de tratamento de condições oculares |
| US11433057B2 (en) * | 2016-05-20 | 2022-09-06 | Vanda Pharmaceuticals Inc. | Method for improving or enhancing cognition |
| CN107188900B (zh) * | 2017-05-27 | 2019-09-06 | 北京师范大学 | α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
| EP3941352A1 (en) | 2019-03-19 | 2022-01-26 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
| CN116731008B (zh) * | 2023-06-15 | 2025-10-24 | 西北大学 | 标记肺癌靶点烟碱型乙酰胆碱受体的免洗型荧光探针及制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022556A1 (en) * | 2002-09-04 | 2004-03-18 | Novartis Ag | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist |
| WO2010056622A1 (en) | 2008-11-11 | 2010-05-20 | Targacept, Inc. | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS |
| WO2010085724A1 (en) | 2009-01-26 | 2010-07-29 | Targacept, Inc. | Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US5075216A (en) | 1988-09-23 | 1991-12-24 | Cetus Corporation | Methods for dna sequencing with thermus aquaticus dna polymerase |
| ATE267877T1 (de) | 1993-01-07 | 2004-06-15 | Sequenom Inc | Dns - sequenzierung durch massenspektronomie |
| US5498531A (en) | 1993-09-10 | 1996-03-12 | President And Fellows Of Harvard College | Intron-mediated recombinant techniques and reagents |
| US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| CA2403937A1 (en) | 2000-04-05 | 2001-10-18 | Glaxo Group Limited | Iterative analysis of non-responding population in the design of pharmacogenetic studies |
| GB0010955D0 (en) * | 2000-05-05 | 2000-06-28 | Novartis Ag | Organic compounds |
| DE10156719A1 (de) | 2001-11-19 | 2003-05-28 | Bayer Ag | Heteroarylcarbonsäureamide |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| DE10211416A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Essig- und Propionsäureamide |
| DE10211415A1 (de) | 2002-03-15 | 2003-09-25 | Bayer Ag | Bicyclische N-Biarylamide |
| DE10234424A1 (de) | 2002-07-29 | 2004-02-12 | Bayer Ag | Benzothiophen-, Benzofuran- und Indolharnstoffe |
| AU2003276919B2 (en) | 2002-09-25 | 2013-05-16 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| US20050245531A1 (en) | 2003-12-22 | 2005-11-03 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| PE20060437A1 (es) | 2004-06-18 | 2006-06-08 | Novartis Ag | COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| AU2004325725A1 (en) | 2004-12-10 | 2006-06-22 | Abbott Laboratories | Fused bicycloheterocycle substituted quinuclidine derivatives |
| GB0521508D0 (en) | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| GB0525673D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| GB0525672D0 (en) | 2005-12-16 | 2006-01-25 | Novartis Ag | Organic compounds |
| TW200813067A (en) | 2006-05-17 | 2008-03-16 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| MX2008014672A (es) | 2006-05-19 | 2009-03-09 | Abbott Lab | Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central. |
| US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
| SA08290475B1 (ar) | 2007-08-02 | 2013-06-22 | Targacept Inc | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه |
| WO2009066107A1 (en) | 2007-11-21 | 2009-05-28 | Astrazeneca Ab | Use of a nicotinic receptor agonist |
| CN102186826B (zh) | 2008-10-13 | 2015-06-17 | 弗·哈夫曼-拉罗切有限公司 | 制备双环5-三氟甲氧基-1h-3-吲唑甲酰胺合成中的吲唑中间体的非重氮化方法 |
| JO3250B1 (ar) * | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
-
2012
- 2012-10-18 EA EA201490832A patent/EA034964B1/ru unknown
- 2012-10-18 EP EP12797979.7A patent/EP2768507B1/en active Active
- 2012-10-18 KR KR1020147010115A patent/KR102043077B1/ko active Active
- 2012-10-18 CA CA3083244A patent/CA3083244C/en active Active
- 2012-10-18 CN CN201280051452.1A patent/CN103930112B/zh active Active
- 2012-10-18 WO PCT/IB2012/055692 patent/WO2013057687A2/en not_active Ceased
- 2012-10-18 ES ES12797979T patent/ES2776996T3/es active Active
- 2012-10-18 AU AU2012324458A patent/AU2012324458B2/en active Active
- 2012-10-18 MX MX2014004621A patent/MX374644B/es active IP Right Grant
- 2012-10-18 JP JP2014536391A patent/JP6162705B2/ja active Active
- 2012-10-18 CA CA2852268A patent/CA2852268C/en active Active
- 2012-10-18 BR BR112014007485-2A patent/BR112014007485B1/pt active IP Right Grant
- 2012-10-18 IN IN3647CHN2014 patent/IN2014CN03647A/en unknown
- 2012-10-18 JO JOP/2012/0311A patent/JO3766B1/ar active
- 2012-10-19 TW TW101138792A patent/TWI635861B/zh active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022556A1 (en) * | 2002-09-04 | 2004-03-18 | Novartis Ag | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist |
| WO2010056622A1 (en) | 2008-11-11 | 2010-05-20 | Targacept, Inc. | TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS |
| WO2010085724A1 (en) | 2009-01-26 | 2010-07-29 | Targacept, Inc. | Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
Also Published As
| Publication number | Publication date |
|---|---|
| JO3766B1 (ar) | 2021-01-31 |
| WO2013057687A3 (en) | 2013-07-11 |
| EP2768507A2 (en) | 2014-08-27 |
| TW201322980A (zh) | 2013-06-16 |
| BR112014007485A2 (pt) | 2017-04-04 |
| EA034964B1 (ru) | 2020-04-13 |
| CN103930112B (zh) | 2018-11-09 |
| EA201490832A1 (ru) | 2015-12-30 |
| CA2852268C (en) | 2020-08-25 |
| JP6162705B2 (ja) | 2017-07-12 |
| MX2014004621A (es) | 2014-08-22 |
| ES2776996T3 (es) | 2020-08-03 |
| BR112014007485B1 (pt) | 2022-05-31 |
| TWI635861B (zh) | 2018-09-21 |
| CN103930112A (zh) | 2014-07-16 |
| MX374644B (es) | 2025-03-06 |
| EP2768507B1 (en) | 2019-12-11 |
| CA3083244C (en) | 2023-01-03 |
| WO2013057687A2 (en) | 2013-04-25 |
| AU2012324458B2 (en) | 2016-05-19 |
| JP2015501306A (ja) | 2015-01-15 |
| CA2852268A1 (en) | 2013-04-25 |
| CA3083244A1 (en) | 2013-04-25 |
| AU2012324458A1 (en) | 2014-05-01 |
| KR20140081822A (ko) | 2014-07-01 |
| IN2014CN03647A (enExample) | 2015-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102043077B1 (ko) | 알파 ７ 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성을 예측하는 바이오마커 | |
| CA2566256C (en) | Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof | |
| AU2013313282B2 (en) | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4) | |
| KR102149483B1 (ko) | 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도 | |
| KR102723469B1 (ko) | 타우 발현을 조절하기 위한 올리고뉴클레오티드 | |
| KR20190018515A (ko) | B형 간염 감염을 치료하기 위해 PAPD5 또는 PAPD7 mRNA를 감소시키기 위한 핵산 분자 | |
| TWI334886B (en) | Genetic variants predicting warfarin sensitivity | |
| ES2661050T3 (es) | Biomarcador predictivo de la capacidad de respuesta a tratamiento con activador del receptor nicotínico de acetilcolina alfa-7 | |
| KR20150023904A (ko) | 전립선암의 진단 및 치료에서의 마커의 용도 | |
| US20030099958A1 (en) | Diagnosis and treatment of vascular disease | |
| KR20090087486A (ko) | 타입 ２ 당뇨병의 유전적 감수성 변이 | |
| CN101631876A (zh) | 2型糖尿病的遗传易感性变体 | |
| CA2651376A1 (en) | Method for diagnosis and treatment of a mental disease | |
| CN108624683B (zh) | Usp48基因突变在acth型垂体腺瘤分子诊断中的应用 | |
| CN115362255A (zh) | 用无七之子2(sos2)抑制剂治疗眼科疾患 | |
| CN113767179A (zh) | 脑梗塞发病风险预测方法 | |
| KR102074157B1 (ko) | Itpkc 및 slc11a1 유전자 다형성을 이용한 가와사키병 발병 예측 방법 | |
| CN112534265A (zh) | 预选个体的抗癌治疗及鉴定易患病个体的筛选方法 | |
| KR20240043752A (ko) | 막횡단 단백질 1(kremen1) 억제제를 함유하는 크링글을 사용하여 감소된 골밀도를 치료하는 방법 | |
| CN117795076A (zh) | 用丝裂原活化蛋白激酶激酶激酶15(map3k15)抑制剂治疗代谢病症的方法 | |
| CN111278468A (zh) | 用于脂肪营养不良的自体细胞疗法的人脂肪组织祖细胞 | |
| US20040138441A1 (en) | Novel gene functionally related to dyslexia | |
| CN113825839A (zh) | 用固醇调节元件结合蛋白切割激活蛋白(scap)抑制剂治疗脂质水平升高 | |
| KR100968360B1 (ko) | Ｈｅｒ-2 유전자 복제수 변화에 의해 발생되는 유방암의 진단 방법 | |
| US20030219787A1 (en) | Novel human gene functionally related to dyslexia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20140416 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20171012 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190116 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20190725 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20190116 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| AMND | Amendment | ||
| PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20190725 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20190315 Comment text: Amendment to Specification, etc. Patent event code: PX09012R01I Patent event date: 20171012 Comment text: Amendment to Specification, etc. |
|
| PX0701 | Decision of registration after re-examination |
Patent event date: 20190828 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20190823 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20190725 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20190315 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20171012 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20191105 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20191106 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20221021 Start annual number: 4 End annual number: 4 |